NCT06161766Completed
Terlipressin in Combined Hepatorenal Syndrome in Patients With Signs of Chronic Renal Disease
Evaluation of the Natural History of Combined Hepatorenal Syndrome in Patients With Signs of Chronic Renal Disease
Source: ClinicalTrials.gov · Last updated 5 Dec 2025
Brief summary (registry, in English)
The aim of this retrospective study is to evaluate the treatment response to terlipressin and albumin in patients with suspicion of HRS-AKI and signs of chronic parenchymal kidney disease (HRS-AKI-like syndrome) compared to patients without signs of chronic parenchymal kidney disease (HRS-AKI).
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 490 (actual)
- First submitted
- 29 Nov 2023
- Start date
- 3 Mar 2024
- Primary completion date
- 31 Dec 2024
- Lead sponsor
- University Hospital Freiburg
- Diseases
- Chronic kidney disease
- NCT number
- NCT06161766
What you commit to
- Study type: Observational
- Participants enrolled: 490
- From 3 Mar 2024 to the primary completion date, 31 Dec 2024
- 4 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients receiving renal replacement therapy at baseline
Other illness
- Patients with cardiac cirrhosis as defined by the development of cirrhosis in a patient with chronic heart failure due to a primary cardiac disease (ischemic cardiomyopathy, hypertensive cardiomyopathy, etc.)
Other
- Uncontrolled shock
- Patients with hepatocellular carcinoma BCLC C or D
Who the study is looking for
- Patients with cirrhosis confirmed by histology or liver stiffness or with unequivocal signs in ultrasound, endoscopy and/or blood tests hospitalized between 1st of January 2018 and 31st of December 2022.
- Evidence of ascites due to portal hypertension
- Clinical suspicion of HRS-AKI or HRS-AKI-like syndrome (in case of previously diagnosed CKD)
- Pre-existing data on kidney function (SCr and eGFR) minimum 3 months prior to admission in a stable situation
- Dip stick urine test results (screening for proteinuria and hematuria) before initiation of AKI-treatment
- Vasoactive treatment for the management of HRS-AKI, as defined by the administration of terlipressin or noradrenalin plus albumin
- Age ≥ 18 years old
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (4)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University Medical Center Freiburg Coordinator of this site? Confirm its status | Freiburg im Breisgau | Germany | Unknown status |
| University Medical Center Jena Coordinator of this site? Confirm its status | Jena | Germany | Unknown status |
| University Medical Center Mainz Coordinator of this site? Confirm its status | Mainz | Germany | Unknown status |
| University Hospital Munster Coordinator of this site? Confirm its status | Münster | Germany | Unknown status |
Related publications
- Chronic Kidney Disease Does Not Influence Response to Terlipressin in Hepatorenal Syndrome-Acute Kidney Injury.Clin Gastroenterol Hepatol · 2026 · PMID 41265546
This page is information, not medical advice. Discuss any trial with your doctor.